share_log

《大行報告》中金對中藥及醫藥股投資評級及目標價(表)(更正)

Investment rating and Target Price of CICC on traditional Chinese Medicine and Pharmaceutical stocks in the Daxing report (Table) (corrected)

即市頭條 ·  Jan 5, 2022 02:40

CICC released a report last Friday (December 31) setting out the investment ratings and target prices of traditional Chinese medicine and mainland pharmaceutical stocks:

Target price of "investment rating" for shares (HK $)

Baiyunshan (00874.HK) "outperforms the industry" 25 yuan

Tongrentang Technology (01666.HK) "outperforms the industry" 7.1yuan

Guorentang traditional Chinese Medicine (03613.HK) "outperforms the industry" 13.3 yuan

Chinese traditional medicine (00570.HK) "outperforms the industry" 5.05 yuan

Alibaba Health Information Technology (00241.HK) "outperforms the industry" 10.9 yuan

JD Health (06618.HK) "outperforms the industry" 102.4 yuan

China Resources Pharmaceutical (03320.HK) "outperforms the industry" 5.42 yuan

------------------------------------------------------

Stock market forecasts price-to-earnings ratio for 2022

Baiyun Mountain is 7.5 times as much as it is.

Tongrentang Technology Co., Ltd. 13.8 times

The medicine of Guorentang is 14.7 times.

9.7 times of Chinese traditional medicine

China Resources Pharmaceutical Co., Ltd. 5.1 times

Correction: 2022-01-03 15:07:36 "Big Bank report" CICC's investment rating and target price on traditional Chinese medicine and pharmaceutical stocks (table)

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment